Junshi Biosciences & LEO Pharma: A Win-Win Partnership for Toripalimab in Europe

In a strategic move that underscores its commitment to global expansion, Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) has announced a commercialization partnership with LEO Pharma for its flagship drug, toripalimab, in Europe. This collaboration, which leverages the strengths of both companies, is set to bring high-quality, innovative treatments to patients across up to 32 European countries.



Toripalimab, an anti-PD-1 monoclonal antibody independently developed by Junshi Biosciences, has already made a significant impact in various markets worldwide. With approvals in over 35 countries and regions, including China, the US, India, and Hong Kong SAR, toripalimab has demonstrated its potential to provide substantial benefits to patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). The drug's recent approval in Europe further solidifies Junshi Biosciences' position as a leading innovator in the biopharmaceutical industry.

Under the agreement, LEO Pharma will be responsible for toripalimab's distribution, promotion, and sales in up to 32 European countries, including all member states of the European Union (EU) and the European Economic Area (EEA), as well as Switzerland and the United Kingdom. TopAlliance Biosciences Europe, a wholly-owned subsidiary of Junshi Biosciences, will retain the role of Marketing Authorization Holder (MAH) for toripalimab in Europe, overseeing product development, manufacturing, registration, pharmacovigilance, and quality management. LEO Pharma will make payments, including an upfront payment, milestone payments for subsequently approved indications, and a revenue share of a double-digit percentage on the net sales of toripalimab throughout the collaboration territory.

This partnership is a win-win for both companies, as it allows Junshi Biosciences to expand its global footprint while leveraging LEO Pharma's mature distribution network and rich marketing expertise in local markets. By combining their strengths in R&D, manufacturing, and commercialization, toripalimab is poised to be efficiently integrated into the European markets, benefiting local patients in need. Additionally, LEO Pharma has the option to potentially co-commercialize oral programs for dermatology outside the United States, further strengthening the partnership and creating additional opportunities for collaboration.

As Junshi Biosciences continues to implement its 'In China, For Global' strategy, this partnership with LEO Pharma is a testament to the company's commitment to providing high-quality, innovative therapies from China to patients worldwide. With a diversified R&D pipeline comprising over 50 drug candidates and four approved innovations, Junshi Biosciences is well-positioned to capitalize on the growing demand for innovative treatments in the global market.

In conclusion, the commercialization partnership between Junshi Biosciences and LEO Pharma for toripalimab in Europe is a strategic move that aligns with both companies' goals and is set to bring significant benefits to patients across the continent. By leveraging their respective strengths and combining their expertise, this collaboration is poised to create valuable synergies and drive continued growth for both companies. As Junshi Biosciences continues to expand its global footprint, investors can expect the company to deliver on its promise of providing world-class, trustworthy, and affordable therapies to patients worldwide.